Suzhou Ribo Life Science Co., Ltd.
Suzhou Ribo Life Science Co., Ltd. has 1 licensing announcement in this dataset, dated 2026-02-11.
- Country / operating region
- China
- Ticker
- 06938.HK
- Headquarters
- 查無
- Founded
- 查無
- Business
- RNAi therapeutics research and development
- Website
- www.ribolia.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| Six siRNA programs | 查無 | other | preclinical | 2026-02-11 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2026-02-11 | Madrigal Pharmaceuticals, Inc. | Six siRNA programs | USD 60m | 查無 | 查無 | ≤ USD 4400m | Licensors Suzhou Ribo Life Science Co., Ltd.; Ribocure Pharmaceuticals AB |
| Counterparty | Territory | Royalties |
|---|---|---|
| Madrigal Pharmaceuticals, Inc. | Worldwide | Potential royalties on net sales. |
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無